70.78

7.50% -5.74

Transmedics Group Inc (TMDX)

Overview News Price History Option Chain Financials Discussions Forecast

Transmedics Group Inc stock is traded at $70.78, with a volume of 1.05M. It is down -7.50% in the last 24 hours and down -19.16% over the past month. TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Previous Close:

$76.52

Open:

$76.52

24h Volume:

1.05M

Relative Volume:

1.18

Market Cap:

$2.45B

Revenue:

$635.89M

Net Income/Loss:

$171.92M

P/E Ratio:

16.25

EPS:

4.357

Net Cash Flow:

$151.36M

1W Performance:

-9.10%

1M Performance:

-19.16%

6M Performance:

-35.14%

1Y Performance:

-38.81%

1-Day Range:

$70.03

$76.52

1-Week Range:

$70.03

$80.42

52-Week Range:

$60.10

$156.00

Transmedics Group Inc Stock (TMDX) Company Profile

Name

Transmedics Group Inc

Sector

Healthcare (1052)

Industry

Medical Devices (143)

Phone

(978) 552-0900

Address

200 MINUTEMAN ROAD, ANDOVER, MA

Employee

898

Twitter

@transmedics

Next Earnings Date

2026-11-04

Latest SEC Filings

TMDX's Discussions on Twitter

Compare TMDX vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TMDX Transmedics Group Inc	70.78	2.45B	635.89M	171.92M	151.36M	4.357
ABT Abbott Laboratories	104.89	181.50B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	94.75	121.20B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	294.66	113.02B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	44.39	64.33B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.60	49.92B	6.30B	1.07B	1.09B	1.8406

Transmedics Group Inc Stock (TMDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-26	Initiated	Barclays	Overweight
Jul-28-26	Initiated	UBS	Neutral
May-06-26	Downgrade	Oppenheimer	Outperform → Perform
Oct-23-25	Upgrade	Needham	Hold → Buy
Oct-13-25	Initiated	Jefferies	Buy
Sep-16-25	Initiated	Evercore ISI	Outperform
Sep-04-25	Initiated	Stifel	Hold
Dec-17-24	Downgrade	JP Morgan	Overweight → Neutral
Nov-22-24	Downgrade	Needham	Buy → Hold
Oct-29-24	Reiterated	Needham	Buy
Oct-29-24	Reiterated	Oppenheimer	Outperform
Sep-24-24	Initiated	Robert W. Baird	Outperform
Aug-21-24	Initiated	Needham	Buy
Jun-06-24	Initiated	Cantor Fitzgerald	Overweight
Jun-04-24	Initiated	Stephens	Overweight
Mar-28-24	Initiated	Piper Sandler	Overweight
Jul-19-23	Initiated	Robert W. Baird	Outperform
Aug-02-22	Upgrade	JP Morgan	Neutral → Overweight
Oct-08-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-07-20	Initiated	Oppenheimer	Outperform
May-28-19	Initiated	Canaccord Genuity	Buy
May-28-19	Initiated	Cowen	Outperform
May-28-19	Initiated	JP Morgan	Overweight
May-28-19	Initiated	Morgan Stanley	Equal-Weight

View All

Transmedics Group Inc Stock (TMDX) Latest News

Oct 13, 2026

Is TransMedics Group (NASDAQ:TMDX) Still Worth Watching After Target Trim? - Kalkine Media

Oct 13, 2026

Oct 07, 2026

Is TransMedics Group (NASDAQ:TMDX) Ready For Its Next Big Move? - Kalkine Media

Oct 07, 2026

Oct 01, 2026

Is TransMedics Group (NASDAQ:TMDX) Facing a Real Market Test? - Kalkine Media

Oct 01, 2026

Sep 29, 2026

TransMedics CFO Fernando N. Araujo Files Initial SEC Ownership Disclosure Reporting No Shares - Kalkine Media

Sep 29, 2026

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too? - The Globe and Mail

Sep 29, 2026

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too? - The Motley Fool

Sep 29, 2026

[Form 3] TransMedics Group, Inc. Initial Statement of Beneficial Ownership - Stock Titan

Sep 29, 2026

Sep 24, 2026

Viking Therapeutics drops 15% after $500M stock offering; Jaguar Health falls 25% without news. - Pluang

Sep 24, 2026

Sep 23, 2026